-
Liproxstatin-1 HCl: Ferroptosis Assay Guide
2026-08-20
Build more discriminating ferroptosis assays with Liproxstatin-1 HCl, from lipid-peroxidation rescue experiments to mechanistic studies of the mitochondrial calcium–GPX4 axis. The workflow also shows how to separate ferroptotic rescue from nonspecific protection in renal and hepatic injury models.
-
LY2886721: From Target Engagement to Data
2026-08-20
LY2886721 is a potent BACE inhibitor for dissecting amyloid precursor protein processing and amyloid beta reduction. This guide presents an interpretation-first framework that connects biochemical activity, cellular biomarkers, neuronal function, and in vivo translational readouts.
-
Astrocytic GAT-3 in Dentate Gyrus Synaptic Plasticity
2026-08-19
The reference study identifies astrocytic GAT-3 as an active regulator of dentate gyrus synaptic transmission rather than merely a GABA-clearance transporter. By linking GAT-3-dependent astrocyte calcium signaling to presynaptic GluN2B-containing NMDA receptors and contextual fear memory, it provides a cellular mechanism connecting glial transport to hippocampal cognition.
-
Verapamil HCl Workflows for Calcium Signaling
2026-08-19
Verapamil HCl supports controlled studies of calcium-dependent excitability, apoptosis, inflammation, and bone turnover. This guide connects practical cell-based workflows with the reference study’s TXNIP-centered osteoporosis findings, while separating evidence-backed observations from optimization starting points.
-
Aβ40 as a Translational Model of Amyloid Biology
2026-08-18
Amyloid Beta-Peptide (1-40) (human) is more than an aggregation reagent: it is a controllable system for connecting peptide state, calcium-dependent membrane interactions, and disease-relevant phenotypes. This article outlines how translational researchers can use Aβ40 to build better mechanistic models, select meaningful controls, and interpret findings without overstating their clinical relevance.
-
HBTU Workflows for Responsive Peptide Design
2026-08-18
HBTU enables rapid, mild peptide bond formation for complex peptide sequences and enzyme-responsive amphiphiles. This guide connects solid phase peptide synthesis, reaction monitoring, troubleshooting, and assay translation while keeping synthetic performance distinct from biological validation.
-
HMGCS2 Loss, LysoPC, and Pulmonary Fibrosis
2026-08-17
Yang et al. identify injured alveolar type II epithelial cells as a major source of accumulated lysophosphatidylcholine during experimental pulmonary fibrosis and show that these lipids activate lung fibroblasts. Their mechanistic data connect reduced epithelial HMGCS2 to impaired lipid degradation through a PPARα–CPT1A/CPT2 axis, offering a framework for lipid signaling pathway analysis and target validation.
-
Amyloid Beta-Peptide (1-40): Fibril Assays
2026-08-17
Build more reproducible Alzheimer’s disease models with a defined Aβ40 substrate for aggregation, imaging, and neurotoxicity workflows. A ratiometric ruthenium-probe strategy adds practical sensitivity by separating aggregation-responsive phosphorescence from a comparatively stable fluorescence reference.
-
BHQ: From SERCA Biology to HSC Translation
2026-08-16
2,5-di-tert-butylbenzene-1,4-diol (BHQ) is more than a calcium-store perturbant. As a selective SERCA inhibitor, it offers translational researchers a way to connect calcium homeostasis disruption with ER stress, CXCR4 biology, vascular physiology, and hematopoietic stem cell mobilization.
-
TG003: Cdc2-like Kinase Inhibitor for Splicing
2026-08-15
TG003 is a potent Cdc2-like kinase inhibitor that preferentially inhibits Clk1 and Clk4 and modulates serine/arginine-rich protein phosphorylation. Its strongest research use is controlled investigation of alternative splicing modulation, while ovarian-cancer resistance findings for CLK2 provide mechanistic context rather than direct proof of TG003 efficacy.
-
β-Elemene Inhibits Adipogenesis via AMPK
2026-08-14
The reference study shows that β-Elemene suppresses MDI-induced lipid accumulation in 3T3-L1 adipocytes and improves glucose consumption in a dexamethasone-induced insulin-resistance model. Its main contribution is linking these metabolic effects with restoration of AMPK pathway activity, while also defining a practical cell-based workflow for investigating adipogenesis.
-
CLK2 and Platinum Resistance in Ovarian Cancer
2026-08-14
The reference study identifies CLK2 as a clinically relevant determinant of platinum resistance in ovarian cancer and defines a CLK2–BRCA1 Ser1423 DNA-repair axis. Its tissue, cellular, mechanistic, and xenograft evidence provides a framework for testing CLK2-directed interventions while highlighting the need to distinguish CLK2 biology from broader Cdc2-like kinase and splicing effects.
-
Nitazoxanide Targets IMPA1-RAGE in Pulmonary Hypertension
2026-08-13
The reference study identifies IMPA1 as a direct molecular target of nitazoxanide and links disruption of the IMPA1-RAGE interaction to reduced PI3K/Akt/mTOR signaling, glycolysis, pulmonary artery pressure, and vascular remodeling. Its multi-model design provides a mechanistic framework for evaluating remodeling-directed therapies, while also clarifying which complementary assays are appropriate for future pulmonary hypertension studies.
-
Sunitinib: RTK Inhibition in Cancer Research
2026-08-13
Sunitinib is an orally bioavailable, multi-targeted receptor tyrosine kinase inhibitor used to study VEGFR, PDGFR, KIT, and RET signaling. Product data support low-nanomolar kinase inhibition, apoptosis and G0/G1 arrest in cancer models, while peer-reviewed evidence identifies ATRX status as a relevant variable for RTK-inhibitor sensitivity in high-grade glioma.
-
TG003: Cdc2-like Kinase Inhibitor Guide
2026-08-12
TG003 Cdc2-like kinase (Clk) inhibitor (SKU B1431) offers a defined biochemical and formulation profile for alternative splicing, viability, and cytotoxicity workflows. This scenario-based guide explains dosing, controls, interpretation limits, and vendor-selection criteria for more defensible cell-based experiments.